Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an abstract supporting the clinical evaluation of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet developed for the prevention and treatment of chemo-radioation therapy-induced severe oral mucositis (SOM) in patients with head and neck cancer, has been accepted for oral presentation at the upcoming 57th American Society for Radiation Oncology (ASTRO) Annual Meeting, being held October 18-21, 2015 in San Antonio, TX.
In an oral presentation during the ePoster 16 Discussion Session “Head and Neck V” on Wednesday, October 21, Dr. Jordi Giralt, M.D., Ph.D., Head of the Radiation Oncology Service at Vall d’Hebron University Hospital in Barcelona, Spain, and investigator of the Validive® Phase 2 trial, will discuss compliance and patient acceptability of Validive® findings from the global Phase 2 randomized double-blind, placebo-controlled study.
Logistical details for the oral presentation and poster session include:
Title: Compliance and Patient Acceptability of Clonidine Mucoadhesive Buccal Tablet (Clonidine Lauriad) to Prevent Severe Radiomucositis in Head and Neck Cancer Patients
Jordi Giralt, M.D., Ph.D.
Head of the Radiation Oncology Service at Vall d’Hebron University Hospital, Barcelona, Spain
Oral ePoster 16 Discussion: Head and Neck V
Presentation # 1139
Wednesday, October 21, 2015
10:45 a.m. – 12:15 p.m. CT
Room 102 A/B, Henry B. Gonzalez Convention Center